Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Apex Biotech Research Pty Ltd. maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is localized within 1 distinct art unit and assigned to 1 distinct examiner, reflecting a narrow channel of engagement with the patent office. Such a concentrated portfolio structure means that the company's current legal strategy is tied to the specific examination standards of a single administrative group.
The busiest examiner assigned to the portfolio is BELL, SARA ELIZABETH, who is currently managing 1 busiest examiner pending office action. This individual examiner holds the entirety of the company's active prosecution workload, making their specific interpretation of biotechnology statutes critical to the firm's immediate success. The presence of only 1 pending office action suggests a highly selective or early-stage approach to securing patent rights in this technical domain.
Because the portfolio involves only 1 distinct examiner and 1 distinct art unit, the applicant faces a singular set of procedural expectations. This lack of diversification across different examiners or art units simplifies the management of the pending office action but also increases the impact of a single examiner's discretion. Future expansion into other areas of Biotechnology & Pharmaceuticals would be required to broaden the company's examiner exposure beyond this current state.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246931 | FORMULATIONS COMPRISING BOTANICAL EXTRACTS | BELL, SARA ELIZABETH | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246931 | FORMULATIONS COMPRISING BOTANICAL EXTRACTS | BELL, SARA ELIZABETH | 34d |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18246931 | FORMULATIONS COMPRISING BOTANICAL EXTRACTS | BELL, SARA ELIZABETH | 1625 | §101§103§112 | Non-Final OA | 34d | Pending | Mar 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial